CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
Development Program Can Support Approval, No New Studies Requested
NDA Submission by CytRx Being Prepared
Conference Call on April 19, 2017 at 8:30 AM EDT/ 5:30 AM PDT
LOS ANGELES, April 19, 2017 -- (Healthcare Sales & Marketing Network) -- CytRx... Biopharmaceuticals, Oncology, FDA CytRx, aldoxorubicin, soft tissue sarcoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Conferences | Marketing | Pharmaceuticals | Sarcomas | Soft Tissue Sarcoma | Study